Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Classical Hodgkin LymphomaRecurrent Hodgkin Lymphoma1 moreThis phase II trial evaluates how effective 560 mg of ibrutinib taken by mouth daily is in the treatment of classical Hodgkin lymphoma which recurs or does not respond to initial treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, by altering the environment around the tumor or by affecting the immune system.
DS-3201b in Participants With Lymphomas
LymphomaMalignant1 moreDS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research. Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their disease: has come back after remission is not responding to current treatment This study has three parts: Dose Escalation is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. Dose Expansion is to: find out how effective DS-3201b is for rare types of NHL collect additional safety data Drug-Drug Interaction (DDI) Cohort (US Only) is to evaluate the effect of DS-3201b on the pharmacokinetics (PK) midazolam and digoxin when co-administered to patients with NHL
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects...
Mantle Cell Lymphoma (MCL)A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell Lymphoma7 moreThe purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they can test it in future participants to see if it is effective in treating their relapsed/refractory B-cell cell cancers. This study will also look at whether 19(T2)28z1xx CAR T cells work against participants' cancer.
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse...
Diffuse Large B Cell LymphomaThis is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with diffuse large B-cell lymphomas.
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma...
Anaplastic Large Cell LymphomaPeripheral T Cell Lymphoma3 moreThis is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
NHLNon Hodgkin Lymphoma2 moreThis is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin...
Hodgkin LymphomaAdult4 moreThis is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Non-Hodgkins LymphomaChronic Lymphocytic LeukemiaThe purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular...
LymphomaThe purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma